T1	Participants 51 144	infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement
T2	Participants 186 273	anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study
T3	Participants 321 440	inflammation and joint destruction in rheumatoid arthritis (RA) patients who have not responded clinically to treatment
T4	Participants 919 948	receiving infliximab plus MTX
T5	Participants 1252 1294	ACR20 nonresponders to infliximab plus MTX
T6	Participants 1582 1617	patients receiving MTX plus placebo
T7	Participants 1626 1664	patients receiving infliximab plus MTX
T8	Participants 2387 2425	patients without clinical improvement,
